trending Market Intelligence /marketintelligence/en/news-insights/trending/fs39e_9anizvskh_nqeoug2 content esgSubNav
In This List

UK NICE recommends Biogen's Avonex, other MS drugs after price cuts

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


UK NICE recommends Biogen's Avonex, other MS drugs after price cuts

The U.K. National Institute for Health and Care Excellence recommended Teva Pharmaceutical Industries Ltd, Biogen Inc. and Merck Serono SA's multiple sclerosis drugs after the companies cut prices for the therapies.

Multiple sclerosis, or MS, is a potentially disabling autoimmune disease — where the immune system attacks a sufferer's body by mistake — that affects the brain and spinal cord.

In draft guidance, the price watchdog recommended Teva's Copaxone, Biogen's Avonex, Merck Serono's Rebif as options for treating people with relapsing-remitting MS.

Novartis AG's Extavia — the sole MS therapy approved in the previous draft guidance — was also recommended in the guidance.

NICE did not recommend Bayer AG's Betaferon for the same indication because the therapy was not cost effective.